Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYP0015 tablets in combination therapy for advanced solid tumors (Phase Ib/II, China)
CTR20260567Phase 2Terminated
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Feb 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ERAS-0015 in Nonhematologic neoplasms, sponsored by Guangzhou JOYO Pharma. Primary endpoints: Dose-limiting toxicity (DLT) in Phase Ib (dose exploration), Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) in Phase Ib and 1 more. Started Feb 2026; status: terminated.
02
Drugs
ERAS-0015
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260567.